Drug Trial Radar · NCT05015686
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
Last checked: Nov 19, 2026Latest source record: Mar 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,400
Planned (sponsor's estimate)
Start
Sep 30, 2021
Primary completion
Feb 9, 2022
Study completion Sep 20, 2026
Sponsor
- Lead sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity of a two doses vaccination of investigational vaccine with 0,28 day, 0,42 day and 0,56 day immunization schedule in population aged ≥13 years old.
Conditions
- Varicella
Interventions
Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., LtdBiological
live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,LtdBiological
live varicella-zoster virus in trehalose,human serum albumin,sodium glutamate,sucrose,glucose,carbamide,arginine and injection water per injection
Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., LtdBiological
live varicella-zoster virus in 0·5 mL of sucrose, sodium glutamate,sodium chloride,potassium chloride,sodium dihydrogen phosphate, potassium dihydrogen phosphate and injection water per injection
PlaceboBiological
Sodium chloride and distilled water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion rate of the antibodyTime frame: Day 28 after the whole schedule
- GMT of the antibodyTime frame: Day 28 after the whole schedule
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yucheng Center for Disease Control and Prevention
Shangqiu, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.